Share on StockTwits

Dyax Corp. (NASDAQ:DYAX) CFO George V. Migausky unloaded 16,000 shares of Dyax Corp. stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $8.26, for a total transaction of $132,160.00. Following the transaction, the chief financial officer now directly owns 85,350 shares of the company’s stock, valued at approximately $704,991. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Bank of America reiterated a “positive” rating on shares of Dyax Corp. in a research note on Wednesday, May 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $12.00.

Dyax Corp. (NASDAQ:DYAX) traded up 2.38% during mid-day trading on Tuesday, hitting $8.805. The stock had a trading volume of 1,174,965 shares. Dyax Corp. has a 52 week low of $3.08 and a 52 week high of $10.99. The stock has a 50-day moving average of $7.24 and a 200-day moving average of $8.21. The company’s market cap is $1.196 billion.

Dyax Corp. (NASDAQ:DYAX) last announced its earnings results on Wednesday, April 30th. The company reported ($0.05) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.05). Analysts expect that Dyax Corp. will post $-0.20 EPS for the current fiscal year.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.